I agree with your all your comments. The recognition by Governments around the world of the cost they have to bear to support overweight people will ensure that they financially contribute to any medical forays into drug development that reduces weight issues.
The potential share that RMD may obtain of the currently large, untouched portion of the total addressable sleep apnea market may smooth out any sales regression in the short-term but scientific development is an issue that needs to be watched closely as a long-term holder of this stock.
Buy RMD now and get great upside returns in a year or two, page-60
Add RMD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$32.04 |
Change
0.110(0.34%) |
Mkt cap ! $20.38B | |||
| Open | High | Low | Value | Volume |
| $31.95 | $32.16 | $31.87 | $18.51M | 578.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6284 | $35.24 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $29.80 | 10608 | 1 |
View Market Depth
| Last trade - 15.59pm 17/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$32.03 |
Change
0.110 ( 0.11 %) |
||||
| Open | High | Low | Volume | ||
| $31.94 | $32.15 | $31.88 | 540165 | ||
| Last updated 15.59pm 17/06/2024 ? | |||||
| RMD (ASX) Chart |
